Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...
To reduce papillary tumor recurrence, optimized intravesical mitomycin C combined with fluorescence blue-light cystoscopy shows promise. Fluorescence blue-light cystoscopy along with optimized ...
All right. Well, good afternoon, good morning to everyone. This is Photocure ASA Fourth Quarter and Full Year 2025 Results. I'm Dan Schneider, President and CEO. Today with me is Erik Dahl, CFO; and ...
OSLO, Norway, Feb. 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.1 million in the fourth quarter of 2025 (Q4 2024: NOK 128.6 million), and a ...
detection of CIS, lesion detection rates, false positive rate, and safety. Key findings: Compared with WLC, the proportion of patients with additional bladder cancer lesions detected by BLC was 43.3% ...
Reno, Nevada (UroToday.com) -- Photocure announces the publication of the study “Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a ...
OSLO, Norway, Dec. 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of a health economics abstract from the BRAVO study at the Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results